Sekisui XenoTech Expands Partnership for Japanese Collection of Research Bioresources Cell Bank (JCRB) Distribution
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
After 3 years as the official distributor of JCRB cell lines in North America, Sekisui XenoTech has expanded its agreement with the National Institute of Biomedical Innovation to include distribution to Europe. Scientists in both regions will now be able to utilize Sekisui XenoTech in order to easily receive just about any type of cell line that they may need for their research.
The JCRB Cell Bank provides over 1,200 cell lines, including:
• General cells
• Luciferase-expressing cancer cells
• Mouse homozygous mutant ES cells
• Immortalized Mesenchymal stem cells
• Genetically-modified cells
“We are proud to provide JCRB cell line access to European biotechs, pharmas and academia to help facilitate cutting-edge research,” commented Muddasar Farooq, Sekisui XenoTech’s European Territory Manager. He continued, “Our team has worked hard to make this possible. This achievement aligns well with our company’s mission – to lead collaborations with the world’s principal researchers and scientific experts, advancing life-enhancing therapies with unparalleled insight and interpretation through high value products and bespoke services.”
Some of the most commonly requested cell lines include:
• HuH-7 well-differentiated human hepatocellular carcinoma cell line
• Kuramochi undifferentiated carcinoma, ascites human ovary cell line
• KMS-11 human hemo-lymphocytic myeloma cell line
• Ovkate human cell line derived from ovarian tumor
• QGP-1 carcinoembryonic antigen (CEA)-producing human pancreatic ilet cell carcinoma cell line
• MBT2 C3H mouse bladder carcinoma cell line
• Ovsaho human cell line derived from ovarian tumour
• KHYG-1 human natural killer cell line with a p53 point mutation as a model for p53-associated leukemogenesis and a model for differentiation of NK/T cells
• HUH-6 Clone 5 JTC38 human hepatoblastoma cell line from an infant
• JHH-7 HBV integrated human hepato cellular carcinoma cell line
Sekisui XenoTech has received very positive customer feedback about JCRB’s cell lines and the company’s distribution process. A senior scientist at a research institute wrote, “We were searching for companies that marketed a particular cell line of interest to us. The cell line was only available at Sekisui XenoTech. Product arrived on time and viability of cells was very good. Customer service was excellent.” A study director for a contract research organization added, “Information provided with the cell line was more than expected and very detailed. Also had the paper describing cell line work performed.”
A list of cell lines is available on Sekisui XenoTech’s website. Orders can be placed directly with Sekisui XenoTech or through JCRB’s website. Sekisui XenoTech will handle all of the logistics for shipments to laboratories throughout North America and Europe, including Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK and USA.
The JCRB Cell Bank provides over 1,200 cell lines, including:
• General cells
• Luciferase-expressing cancer cells
• Mouse homozygous mutant ES cells
• Immortalized Mesenchymal stem cells
• Genetically-modified cells
“We are proud to provide JCRB cell line access to European biotechs, pharmas and academia to help facilitate cutting-edge research,” commented Muddasar Farooq, Sekisui XenoTech’s European Territory Manager. He continued, “Our team has worked hard to make this possible. This achievement aligns well with our company’s mission – to lead collaborations with the world’s principal researchers and scientific experts, advancing life-enhancing therapies with unparalleled insight and interpretation through high value products and bespoke services.”
Some of the most commonly requested cell lines include:
• HuH-7 well-differentiated human hepatocellular carcinoma cell line
• Kuramochi undifferentiated carcinoma, ascites human ovary cell line
• KMS-11 human hemo-lymphocytic myeloma cell line
• Ovkate human cell line derived from ovarian tumor
• QGP-1 carcinoembryonic antigen (CEA)-producing human pancreatic ilet cell carcinoma cell line
• MBT2 C3H mouse bladder carcinoma cell line
• Ovsaho human cell line derived from ovarian tumour
• KHYG-1 human natural killer cell line with a p53 point mutation as a model for p53-associated leukemogenesis and a model for differentiation of NK/T cells
• HUH-6 Clone 5 JTC38 human hepatoblastoma cell line from an infant
• JHH-7 HBV integrated human hepato cellular carcinoma cell line
Sekisui XenoTech has received very positive customer feedback about JCRB’s cell lines and the company’s distribution process. A senior scientist at a research institute wrote, “We were searching for companies that marketed a particular cell line of interest to us. The cell line was only available at Sekisui XenoTech. Product arrived on time and viability of cells was very good. Customer service was excellent.” A study director for a contract research organization added, “Information provided with the cell line was more than expected and very detailed. Also had the paper describing cell line work performed.”
A list of cell lines is available on Sekisui XenoTech’s website. Orders can be placed directly with Sekisui XenoTech or through JCRB’s website. Sekisui XenoTech will handle all of the logistics for shipments to laboratories throughout North America and Europe, including Austria, Belgium, Bulgaria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK and USA.
